Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study
/in International Publications, Malignant Lymphoma /von 2008-09-22 / Blood 2009 Jan;113(1):18-27The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience
/in Acute Leukemia, Dendritic Cells, International Publications /von 2008-09-20 / Pathol. Oncol. Res. 2009 Jun;15(2):257-67Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination
/in International Publications, Malignant Melanoma /von 2008-09-19 / J. Dermatol. Sci. 2009 Jan;53(1):40-7Cancer immunotherapy by dendritic cells
/in Dendritic Cells, International Publications /von 2008-09-19 / Immunity 2008 Sep;29(3):372-83In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells
/in Hepatocellular Carcinoma, International Publications /von 2008-09-15 / J Transl Med 2008 Sep;6:51Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy
/in Dendritic Cells, International Publications /von 2008-09-01 / J. Immunother. 2008 Sep;31(7):620-32Ovarian cancer detection and treatment: current situation and future prospects
/in International Publications, Ovarian Cancer /von 2008-09-01 / Anticancer Res. 2008 Sep-Oct;28(5B):3135-8Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy
/in Breast Cancer, International Publications /von 2008-09-01 / J. Immunol. 2008 Sep;181(5):3690-7Therapeutic vaccines for non-Hodgkin B-cell lymphoma
/in International Publications, Malignant Lymphoma /von 2008-09-01 / Clin Transl Oncol 2008 Sep;10(9):543-51
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution